SCHEMBL13615225

SCHEMBL13615225

CC(C)(C)c1ccc(NS(=O)(=O)c2ccc(Cl)cc2Cl)cc1F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 11/20 0.55
ITGA1 P56199 4/20 0.53
MEN1 O00255 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
ALOX12 P18054 1/20 0.51
KMT2A Q03164 1/20 0.51
NLRP1 Q9C000 1/20 0.51
CYP3A4 P08684 1/20 0.49
CDK1 P06493 1/20 0.48
CCNB1 P14635 1/20 0.48
CCNA2 P20248 1/20 0.48
CDK2 P24941 1/20 0.48
CDK7 P50613 1/20 0.48
CCNH P51946 1/20 0.48
CCNA1 P78396 1/20 0.48
HDAC1 Q13547 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
SLC22A12 Q96S37 1/20 0.47
CNR2 P34972 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13615181 0.90 ALDH1A1 (0.56) MEN1LMNAMAPTKMT2ACDK1
SCHEMBL13615216 0.90 BRD4 (0.52) PPARGITGA1SLC22A12
SCHEMBL13615251 0.86 CDK1 (0.52) PPARGCYP3A4CDK1CCNB1CCNA2
SCHEMBL13615141 0.85 SLC22A12 (0.54) MEN1LMNAMAPTKMT2AHDAC1
SCHEMBL13615338 0.85 PPARG (0.56) PPARGITGA1MEN1LMNAMAPT
SCHEMBL13615237 0.84 SLC22A12 (0.47) PPARGSLC22A12CNR2
SCHEMBL13615120 0.84 CES1 (0.57) MEN1LMNAMAPTKMT2ACYP3A4
SCHEMBL13629411 0.82 PPARG (0.55) PPARGITGA1MEN1LMNAMAPT
SCHEMBL13615171 0.81 MEN1 (0.48) MEN1LMNAMAPTKMT2ACYP3A4
SCHEMBL13615211 0.81 PKM (0.60) MEN1LMNAMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PPARG 1772/4885ITGA1 2545/4885MEN1 1723/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PPARG 1808/4885ITGA1 2130/4885MEN1 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.